The Helsinki Heart Study: Central Findings and Clinical Implications
- 1 January 1991
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Annals of Medicine
- Vol. 23 (2), 155-159
- https://doi.org/10.3109/07853899109148041
Abstract
This paper describes the central findings and discusses the clinical implications of the Helsinki Heart Study. This was a controlled primary prevention trial to test the hypothesis that using gemfibrozil to lower the concentrations of serum low density lipoprotein (LDL) and very low density lipoprotein (VLDL) and to raise that of high density lipoprotein (HDL) protects subjects against coronary heart disease.This publication has 17 references indexed in Scilit:
- Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with HypercholesterolemiaThe New England Journal of Medicine, 1990
- High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation, 1989
- Reduction of Mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by Combined Treatment with Clofibrate and Nicotinic AcidActa Medica Scandinavica, 1988
- The Helsinki Heart Study: Basic design and randomization procedureEuropean Heart Journal, 1987
- Review of lipid-lowering clinical trials in relation to observational epidemiologic studies.Circulation, 1987
- Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosisAmerican Heart Journal, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- Maximal coronary flow and the concept of coronary vascular reserve.Circulation, 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Heart, 1978